(December 2, 2015, 12:31 PM EST) -- NEW YORK — A New York federal judge on Nov. 20 approved a $286.87 million settlement of claims that Novartis Pharmaceuticals Corp. violated the False Claims Act and the Anti-Kickback Statute through its promotion of its Exjade iron chelation drug and Myfortic immunosuppressant drug (United States of America, ex rel. David Kester v. Novartis Pharmaceuticals Co., No. 11-8196, S.D. N.Y.)....